Valneva (VALN) announced results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Chikungunya was first recognized in Tanzania in 1952, and human infections occurred in Africa at relatively low levels until around 2000 when there was a large outbreak in the Democratic Republic of ...

Valneva has announced positive outcomes from its Phase III trial of the single-shot IXCHIQ chikungunya virus vaccine in ...

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...

A new Guillain-Barre Syndrome (GBS) case emerged in Pune, totaling 111 suspected cases. Efforts are underway to curb the outbreak, including water supply measures and a new ICU. Various samples are ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ ® ...

Chikungunya virus (CHIKV ... the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need.

Partially funded by the Coalition for Epidemic Preparedness Innovations ... of the dose (half dose or full dose) or previous chikungunya infection (CHIKV), and, to a similar extent, to an active ...

today announced positive results for its Phase 2 clinical trial evaluating the safety and immunogenicity of two different dose levels of its single-shot chikungunya vaccine, IXCHIQ ®, in 304 children.